World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
122
Citations
82526
World Ranking
3406
National Ranking
1876

Mitchell L. Shiffman publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mitchell L. Shiffman sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 577 publications — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mitchell L. Shiffman D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mitchell L. Shiffman sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 122 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mitchell L. Shiffman is affiliated with the Bon Secours Health System in the United States. Their research primarily focuses on hepatology within the field of medicine, with a significant emphasis on liver diseases. Shiffman's work spans several subfields including hepatology, epidemiology, surgery, pulmonary and respiratory medicine, and hematology.

Their published research has appeared most frequently in notable medical journals and venues such as the Journal of Hepatology, Hepatology, Clinics in Liver Disease, UNC Libraries, and Alimentary Pharmacology & Therapeutics.

Shiffman's research topics extensively cover various aspects of liver disease diagnosis and treatment, liver diseases and immunity, hepatitis C virus research, liver disease and transplantation, pediatric hepatobiliary diseases and treatments, gallbladder and bile duct disorders, and hepatitis B virus studies.

Frequent collaborators include Kris V. Kowdley, Christopher L. Bowlus, Robert P. Myers, Guy Neff, and Stephen A. Harrison, each of whom has coauthored multiple publications with Shiffman.

Selected recent papers authored or coauthored by Shiffman include:

  • Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials (2020), Journal of Hepatology
  • Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020), Hepatology
  • Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH (2020), Hepatology
  • Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis (2023), New England Journal of Medicine
  • Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations (2020), The American Journal of Gastroenterology

Best Publications

  • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

    Michael W. Fried;Mitchell L. Shiffman;K. Rajender Reddy;Coleman Smith

  • Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

    Michael P. Manns;John G. McHutchison;Stuart C. Gordon;Vinod K. Rustgi

  • Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

    John G. Mchutchison;Stuart C. Gordon;Eugene R. Schiff;Mitchell L. Shiffman

  • Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities

    Arun J. Sanyal;Carol Campbell-Sargent;Faridoddin Mirshahi;William B. Rizzo

  • Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

    Patrick Marcellin;Ting Tsung Chang;Seng Gee Lim;Myron J. Tong

  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

    John G. McHutchison;Eric J. Lawitz;Mitchell L. Shiffman;Andrew J. Muir

  • Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

    Gary L. Davis;Rafael Esteban-Mur;Vinod Rustgi;John Hoefs

  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

    Kris V. Kowdley;Stuart C. Gordon;K. Rajender Reddy;Lorenzo Rossaro

  • Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

    Pouneh Mofrad;Melissa J. Contos;Mahmadul Haque;Carol Sargeant

  • Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B

    Patrick Marcellin;E Jenny Heathcote;Maria Buti;Ed Gane

  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

    Ira M. Jacobson;Stuart C. Gordon;Kris V. Kowdley;Eric M. Yoshida

  • Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

    E. J. Heathcote;M. L. Shiffman;W. G. E. Cooksley;G. M. Dusheiko

  • ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

    Fred Poordad;Christophe Hezode;Roger Trinh;Kris V. Kowdley

  • A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

    F. Nevens;P. Andreone;G. Mazzella;S. I. Strasser

  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

    Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

    Karen L. Lindsay;Christian Trepo;Tobias Heintges;Mitchell L. Shiffman

  • Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

    Alexander J. Thompson;Andrew J. Muir;Andrew J. Muir;Mark S. Sulkowski;Dongliang Ge

  • Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

    Peter Ferenci;Michael W. Fried;Mitchell L. Shiffman;Coleman I. Smith

  • Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.

    Mitchell L. Shiffman;Adrian M. Di Bisceglie;Karen L. Lindsay;Chihiro Morishima

  • A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C

    Peter Hayes;John Plevris

Frequent Co-Authors

Velimir A. Luketic
Velimir A. Luketic Virginia Commonwealth University
Arun J. Sanyal
Arun J. Sanyal Virginia Commonwealth University
Richard K. Sterling
Richard K. Sterling Virginia Commonwealth University
Robert A. Fisher
Robert A. Fisher Beth Israel Deaconess Medical Center
Andrew J. Muir
Andrew J. Muir Duke University
Timothy R. Morgan
Timothy R. Morgan California State University, Long Beach
Gregory T. Everson
Gregory T. Everson University of Colorado Denver
Eric Lawitz
Eric Lawitz The University of Texas at Austin
William M. Lee
William M. Lee The University of Texas Southwestern Medical Center
Mark S. Sulkowski
Mark S. Sulkowski Johns Hopkins University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to several related online degrees and career pathways in the healthcare sector. Online programs offer flexibility and affordability to suit various backgrounds and goals.

If you’re interested in the pharmaceutical field, exploring the cheapest online pharmacy school options can set you on a path toward a PharmD and pharmacy licensure without enormous debt.

For those drawn to the intersection of healthcare and technology, accredited him programs train professionals in managing patient data and overseeing medical records—a field with strong career growth.

Individuals seeking quick entry into healthcare can consider how much is medical billing and coding school to learn about managing insurance claims and reimbursements. This specialized training prepares you for immediate employment in various clinical settings.

Finally, becoming a nurse practitioner offers a rewarding and impactful career. Many students research the cheapest fnp programs online to advance their nursing practice and increase their scope of care.

These online degree options provide multiple pathways into healthcare, each with unique advantages for aspiring professionals.

Best Scientists Citing Mitchell L. Shiffman

Trending Scientists

Recently Published Articles